QLINE

- Q-Line Biotech Limited entered into an Amended and Restated License Agreement with Boule Medical AB, Sweden. - Key commercial benefit is a 25% reduction in license/royalty payable by Q-Line, effective from July 01, 2026. - This is expected to enhance cost efficiency, competitiveness, market outreach, and long-term growth for Q-Line. - The agreement has an initial term of 5 years, extendable for up to 5 more years.